In the summer of 2019, the northeastern United States recorded more than 30 human cases of eastern equine encephalitis virus disease across multiple states, with more than a dozen deaths. Massachusetts, Michigan, and Connecticut each had multiple cases. Public health authorities suspended evening sports, closed parks, and aerially sprayed mosquito breeding areas. The outbreak ended with the first hard frost. The reservoir cycle continued in red maple and white cedar swamps where it had been amplifying for the previous decade, waiting for the next conjunction of warm weather, abundant mosquitoes, and unlucky human bites.
EEE is one of the most lethal arboviruses in North America. CDC counts fewer than a dozen US cases per year on average, but those few cases come with 30 percent mortality and 50 percent rate of permanent neurological deficits in survivors. The disease typically circulates in passerine birds via Culiseta melanura, a swamp-dwelling mosquito that rarely bites humans, but bridge vector species push the virus into people, horses, and other mammals during high-amplification years. This post fits inside the outbreak-aware travel guide and complements the West Nile virus US prevention guide and mosquito-borne disease prevention.
Key Takeaways
- Eastern equine encephalitis virus (EEEV) is a mosquito-borne alphavirus circulating in eastern North America, Central America, and South America.
- The primary mosquito vector for the bird amplification cycle is Culiseta melanura; bridge species like Aedes vexans and Coquillettidia perturbans transmit to mammals.
- Human cases are rare (fewer than a dozen US cases per year on average) but mortality is high (30 percent) and survivor sequelae are severe (50 percent with permanent neurological deficits).
- Endemic US regions include Massachusetts, New Hampshire, Florida, Michigan, Wisconsin, North Carolina, Georgia, New York, and surrounding states.
- No human vaccine exists; horse vaccines protect equine populations and are widely used.
- Prevention is mosquito avoidance during dusk and dawn from late summer through first frost.
What is eastern equine encephalitis?
EEE is caused by eastern equine encephalitis virus, a single-stranded RNA alphavirus in the Togaviridae family. The virus circulates in a tight enzootic cycle between passerine birds (especially perching birds in freshwater swamps) and Culiseta melanura, an ornithophilic mosquito species that feeds almost exclusively on birds.
When the enzootic cycle amplifies during favorable summers, the virus spills into mammal-biting mosquitoes. Aedes vexans, Coquillettidia perturbans, Aedes canadensis, and Aedes sollicitans are the principal bridge vectors that move EEEV into humans, horses, white-tailed deer, alpacas, llamas, emus, pheasants, and other mammals. None of these mammals develop sufficient viremia to re-infect mosquitoes, so they are dead-end hosts.
EEE has been recognized in horses since the 1830s and was identified as a virus in 1933 after a major equine outbreak in coastal New Jersey, Delaware, Maryland, and Virginia. Human cases were first documented in 1938 during a Massachusetts outbreak that killed 25 children.
Where is EEE active?
US case distribution from 2009 to 2023 concentrates in:
| State | Reported cases (2009-2023) |
|---|---|
| Massachusetts | 25+ |
| Florida | 15+ |
| Michigan | 15+ |
| New Hampshire | 10+ |
| Wisconsin | 10+ |
| North Carolina | 10+ |
| Georgia | 8+ |
| New York | 8+ |
Smaller numbers occur in Connecticut, Rhode Island, Vermont, Maine, New Jersey, Louisiana, Texas, Indiana, Ohio, Tennessee, Virginia, Alabama, South Carolina, and Mississippi. Latin American cases follow a different clade and ecological pattern but produce similar clinical disease.
Activity peaks from late July through October, with the highest months being August and September. The virus shuts down with the first hard frost that kills adult mosquitoes. Mild winters and wet springs that flood swamp habitat favor amplification the following summer.
EEE virus has been detected as far north as Quebec and Nova Scotia in mosquito surveillance, with isolated human cases at the northern margins. Climate-driven extension of the active season may push the human risk window earlier and later than the traditional August-to-October peak.
What are the symptoms?
Most EEE infections are asymptomatic or produce mild systemic illness. About 5 percent develop encephalitis, which is severe.
- Asymptomatic to mild (most infections): no symptoms, or 1 to 2 weeks of fever, headache, malaise, myalgia
- Systemic disease without CNS involvement: fever, chills, malaise, arthralgia, myalgia for 1 to 2 weeks; resolves without sequelae
- Encephalitis (5 percent of infections): abrupt onset of high fever, severe headache, vomiting, then within 2 to 4 days altered mental status, seizures, focal neurological deficits, cranial nerve abnormalities, coma
- Severe encephalitis: rapid progression to coma and death within days; survivors often have catastrophic neurological injury
CDC reports overall mortality of 30 percent in clinical (encephalitis) cases. Of survivors, approximately 50 percent have substantial permanent neurological deficits including cognitive impairment, weakness, seizures, behavioral changes, and motor deficits. Younger children and older adults have worse outcomes than middle-aged adults.
Brain MRI shows characteristic lesions in the basal ganglia, thalamus, and brainstem, distinct from but overlapping with herpes simplex encephalitis (which favors temporal lobes) and West Nile encephalitis (which favors thalamus and basal ganglia). CSF shows lymphocytic pleocytosis with elevated protein.
How is EEE diagnosed?
Most US labs do not run EEE testing routinely. Specimens go to CDC's Arbovirus Diseases Branch or to state public health laboratories.
- CSF and serum IgM: detectable within days of symptom onset; useful for acute diagnosis
- CSF PCR: less sensitive than serology because viremia is brief
- Plaque reduction neutralization: distinguishes EEE from cross-reactive arboviruses (West Nile, Powassan, La Crosse) in confirmatory testing
- Acute and convalescent paired serology: seroconversion confirms infection
Clinical suspicion in summer encephalitis with appropriate epidemiology is the key to ordering the right tests. The PCR vs antigen vs serology post covers test selection in similar arboviral diseases.
How is EEE treated?
There is no specific antiviral therapy. Management is supportive intensive care.
- ICU-level monitoring for airway protection, seizure control, intracranial pressure management
- Antiepileptics for seizures (often refractory; status epilepticus is common)
- Mechanical ventilation for respiratory failure or coma
- Rehabilitation for survivors: physical therapy, occupational therapy, speech therapy, cognitive rehabilitation
Investigational therapies including ribavirin, intravenous immunoglobulin, and steroids have been used in case reports without convincing benefit. The aggressive natural history of EEE and the small case numbers make rigorous trials difficult.
How do you prevent EEE?
Mosquito avoidance during the late-summer risk window is the only effective measure.
- Wear long sleeves and pants from dusk through dawn during EEE season (August through first frost in endemic areas)
- Apply DEET 25 to 35 percent or picaridin 20 percent to exposed skin; permethrin-treat clothing
- Use window and door screens; repair tears immediately
- Eliminate standing water around the home: clogged gutters, old tires, planters, birdbaths, kiddie pools
- Limit outdoor activity at dusk during local EEE alerts; some affected towns have postponed evening youth sports during outbreaks
- Local mosquito control programs use larvicides in swamps and adulticides during outbreaks; community spraying is part of the public health response
There is no licensed human vaccine. Veterinary EEE vaccines are widely used in horses and other livestock; equine vaccination has reduced equine cases substantially but does not protect humans. Investigational human vaccines are in early development.
Why are some years much worse than others?
EEE activity varies dramatically year to year because the enzootic cycle in birds and Culiseta melanura depends on:
- Spring precipitation and swamp flooding, which expands Culiseta melanura breeding habitat
- Bird population density and turnover, which sustains amplification
- Summer temperature, which speeds viral replication in mosquitoes
- Bridge vector mosquito abundance, which translates the bird cycle into mammal exposure
- Timing of first frost, which abruptly ends transmission
The 2019 northeastern US outbreak followed a wet spring and warm summer that produced high Culiseta melanura populations through August. Surveillance positive pools climbed steadily before human cases appeared, giving some warning. State and local response (aerial spraying, evening curfews on outdoor activity, public communication) reduced subsequent case rates but could not prevent all human infections.
The climate change and infectious disease post covers how warming temperatures and changing precipitation patterns are likely to affect arbovirus dynamics in coming decades.
FAQ
Why are there so few human cases if the virus is so widespread?
The primary mosquito vector, Culiseta melanura, almost never bites humans. Bridge mosquito species rarely happen to feed on an infected bird and then a human in quick succession. The combination of vector ecology and amplification dynamics keeps human exposure rare even in heavily infected swamp ecosystems. The flip side is that when conditions align, multiple cases cluster in a single summer, as in 2019.
How does EEE compare to West Nile virus?
West Nile is far more common (hundreds to thousands of US cases per year) but less severe per case, with mortality around 5 to 10 percent in neuroinvasive disease. EEE is much rarer (about 11 US cases per year on average) but far more severe, with 30 percent mortality and 50 percent of survivors with permanent deficits. The West Nile virus US prevention guide compares both in detail.
Can EEE survive in mosquito eggs over winter?
There is evidence of vertical transmission in Culiseta melanura, allowing the virus to persist in mosquito eggs through winter and re-emerge with the next generation in spring. This is one mechanism by which EEE re-establishes annual cycles in northern endemic areas. Migratory birds returning from Latin America may also contribute to annual reintroduction.
Should children stop playing outside in EEE outbreaks?
Local public health authorities often issue specific guidance during EEE outbreaks, including evening curfews on youth sports and outdoor activity during peak mosquito hours. Permethrin-treated clothing, repellent, and limiting dusk-to-dawn outdoor exposure during late summer in endemic regions reduce risk. Daytime outdoor activity is generally lower risk because Culiseta melanura and most bridge species are crepuscular.
Is there equine EEE vaccine I can give my horse?
Yes. EEE vaccines for horses are widely available, inexpensive, and effective. The American Association of Equine Practitioners considers EEE vaccination a core recommendation for horses in endemic and adjacent regions. Annual or twice-annual boosters are typical depending on regional risk. Vaccinated horses can still alert local authorities to active transmission when neighboring unvaccinated animals fall ill.